Listing of Claims

No changes have been made in the claims since our last response dated January 19, 2005.

Claim 1 (original): A method for treating an autoimmune disorder in a patient comprising:

a) removing peripheral blood mononuclear cells (PBMC) from said patient;

b) treating said cells with a regulatory composition to generate regulatory T cells, said regulatory composition comprising anti-CD2 and anti-CD3; and;

c) reintroducing said regulatory T cells to said patient to suppress an aberrant immune response.

Claim 2 (original): A method for treating an autoimmune disorder in a patient comprising:

a) removing peripheral blood mononuclear cells (PBMC) from said patient;

b) treating said cells with a regulatory composition to induce said cells to produce immunosuppressive levels of TGF-β; said regulatory composition comprising anti-CD2 and anti-CD3; and;

c) reintroducing said cells to said patient to suppress aberrant immune responses.

Claim 3 (original): A method according to claim 1 or 2, said regulatory composition further comprising TGF-β.

Claim 4 (original): A method according to claim 1 or 2, said regulatory composition further comprising Il-2.

Claim 5 (original): A method according to claim 1 or 2, said regulatory composition further comprising TGF-β and IL-2.

Claim 6 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+.

Claim 7 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and said regulatory composition further comprises TGF-β.

Claim 8 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and said regulatory composition further comprises IL-2.

Claim 9 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and said regulatory composition further comprises TGF-β and IL-2.

Claim 10 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD4+.

Claim 11 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD4+ and said regulatory composition further comprises TGF-β.

Claim 12 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD4+ and said regulatory composition further comprises IL-2.

Claim 13 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD4+ and said regulatory composition further comprises TGF-β and IL-2.

Claim 14 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and CD4+.

Claim 15 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and CD4+ and said regulatory composition further comprises TGF-β.

Claim 16 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and CD4+ and said regulatory composition further comprises IL-2.

Claim 17 (original): A method according to claim 1 or 2, wherein said PBMC comprise CD8+ and CD4+ and said regulatory composition further comprises TGF-β and IL-2.

Claim 18 (original): A method according to claim 1 or 2, wherein said PBMC comprise NK T cells.

Claim 19 (previously presented): A method according to claim 1 or 2, wherein said PBMC comprise NK T cells and said regulatory composition further comprises TGF-β.

Claim 20 (previously presented): A method according to claim 1 or 2, wherein said PBMC comprise NK T cells and said regulatory composition further comprises IL-2.

Claim 21 (previously presented): A method according to claim 1 or 2, wherein said PBMC comprise NK T cells and said regulatory composition further comprises TGF-β and IL-2.

Claim 22 (previously presented): A method according to claim 1 or 2, wherein said aberrant immune response is a cell-mediated autoimmune disease selected from the group

consisting of Hashimoto's disease, polymyositis, inflammatory bowel disease, multiple sclerosis, diabetes mellitus, rheumatoid arthritis, and scleroderma.

Claim 23 (original): A method according to claim 2 wherein said wherein said aberrant immune response is an antibody mediated disease selected from the group consisting of pemphigus vulgaris, myasthenia gravis, hemolytic anemia, thrombocytopenia purpura, Grave's disease, dermatomyositis and Sjogren's disease.